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Capacity of exercise in sarcoidosis: what is the importance of 
cardiopulmonary exercise test in these patients?
Dear Editor
Sarcoidosis is a heterogeneous multisystem 
granulomatous disease of unknown etiology [1]. 
Pulmonary involvement is frequent (90%). Di-
agnosis relies on three criteria: a) a compatible 
clinical and radiologic presentation; b) pathologic 
evidence of noncaseating granulomas; and c) 
exclusion of other diseases with similar findings, 
such as infections or malignancy [2]. The original 
staging of sarcoidosis has been developed from 
lung involvement as determined only by chest 
X-ray (CXR): stage 0 — normal cxr with proven 
extrapulmonary sarcoidosis; stage I — bilateral 
hilar lymphadenopathy without parenchymal 
disease; stage II — bihilar lymphadenopathy with 
parenchymal disease; stage III — parenchymal 
involvement without lymphadenopathy; stage 
IV — fibrosis [3]. Pulmonary function tests (at 
rest) and imaging methods are the most com-
monly used examinations and diagnostic tests in 
the follow-up and evaluation of the therapeutic 
response [4]. Dyspnea and exercise in sarcoidosis 
are often poorly correlated with resting lung func-
tion. Measurement of peak exercise capacity is 
likely to be helpful in assessing and monitoring 
the disease [5]. 
The authors performed a retrospective analy-
sis of the files of 35 patients (13 men and 22 wom-
en) with pulmonary sarcoidosis who underwent 
an incremental cardiopulmonary exercise test 
(CPET) in a cycle ergometer at the Pulmonology 
Department of Coimbra Hospital and University 
Center from January 2008 to June 2018. The 
compromise of exercise capacity and the limiting 
factor during maximum CPET were evaluated, 
along with its relationship with the pulmonary 
function  tests (PFT) and radiological stages of 
the disease.
The following changes in PFT were de-
scribed: obstructive respiratory disorder [forced 
ventilatory volume in one second (FEV1) / forced 
vital capacity (FVC) < 0.70], restrictive respirato-
ry disorder [FVC < 80% predicted and total lung 
capacity (TLC) < 80% predicted] and reduced 
diffusion capacity of carbon monoxide (TL,CO 
< 80% predicted) [6].
CPET was interpreted according with suggest-
ed normal guidelines by the American Thoracic 
Society/American College of Chest Physicians [7] 
and ERS statement on standardisation of CPET in 
chronic lung diseases [8]. Criteria of normality for 
interpretation CPET are the following: VO2max or 
VO2peak > 84% predicted (normal exercise capac-
ity); anaerobic threshold (AT) > 40% VO2max pre-
dicted (wide range of normal 40–80%); maximum 
heart rate (HRmax) > 90% age predicted; heart 
rate reserve (HRR) < 15 beats/min; blood pressure 
< 220/90 mm Hg; O2 pulse > 80%; ventilatory 
reserve (VR): 72 ± 15% (wide normal range); 
respiratory frequency (FR) < 60 breaths/min; 
VE/VCO2 (at AT) > 34; VD/VT < 0.3; pO2 > 80 mm 
Hg; P(A-a)O2 < 35 mm Hg.  
The causes of exercise limitation in CPET 
found in this study were the following: alteration 
in gas exchange, due to desaturation (> 4% from 
baseline or decrease of 10 mm Hg from initial 
PO2), due ventilatory limitation translated by 
dynamic hyperinflation and due to cardiovas-
cular limitation with frequent dysrhythmias 
during exercise. Physical deconditioning were 
defined by decreased VO2max or VO2peak, reduced 
or normal VO2 at AT and decreased or normal 
peak HR.
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The mean age of the patients was 43.1 
± 12.5 years. Regarding smoking habits, 24 sub-
jects (68.6%) were non-smokers and 11 (31.4%) 
smokers or ex-smokers. Twenty-three patients 
(65.7%) had complaints of dyspnea and the rest 
were asymptomatic. Seven persons (20.0%) were 
in stage I of the disease, 13 (37.1%) in stage II, 
9 (25.7%) in stage III and 6 (17.1%) in stage IV. 
Twenty-one patients (60%) were on corticosteroid 
therapy or had already finished. As for the results 
of the functional respiratory study, 14 patients 
(40.0%) had changes (Table 1).
All performed maximum incremental CPET, 
limited by symptoms, on a cycle ergometer. Only 
3 individuals (8.6%) stopped early due to a hy-
pertensive response.
Exercise capacity was normal (% VO2peak 
> 84% predicted) in 2 patients (5.7%), 1 in 
stage I and the other in stage II. The remain-
ing 33 patients (94.3%) had decreased exer-
cise capacity. The average % VO2peak (predict-
ed) in each stadium was as follows: I — 66.83 
± 9.83; II — 61.42 ± 8.41; III — 63.22 ± 16.70; 
IV — 65.83 ± 8.77 (without statistically significant 
difference, p = 0.57). The majority of patients 
(n = 31, 88.6%) reached the anaerobic threshold.
The causes of exercise limitation were the fol-
lowing: a) alteration in gas exchange in 4 (12.1%) 
patients; b) ventilatory limitation in 6 (18.2%) in-
dividuals; c) cardiovascular limitation in 3 (9.1%) 
patients. In the remaining cases, exercise was 
restricted by physical deconditioning.
Table 1. Pulmonary function  tests (PFT) results in 35 sarcoidosis patients and correlation between the results of PFT 
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The correlation between the results of PFT 
and CPET are shown in Table 1. In stage I (n = 7), 
all patients had normal PFT, however, only 1 per-
son had normal CPET (% VO2peak 97% predicted).
In stage II (n = 13), 1 patient had no exercise 
limitation (% VO2peak 110% predicted). One per-
son with restrictive disorder and decreased TL,CO 
had exercise limitations due to alterations in gas 
exchange and cardiovascular limitations. One 
patient with obstructive disorder and decreased 
TL,CO had limitations due to ventilatory changes 
with dynamic hyperinflation and 1 individual 
with obstructive disorder had cardiovascular 
changes during exertion.
In stage III (n = 9), 2 patients with normal 
PFT had exercise limitation due to ventilatory 
alteration with dynamic hyperinflation. Two 
patients with obstructive disorder (one also with 
decreased TL,CO) had ventilatory changes in CPET.
In stage IV (n = 6), the 3 patients with normal 
PFT had exercise limitation (1 due to alterations 
in gas exchange, 1 due to ventilatory limitations 
and 1 due to cardiovascular changes). Two pa-
tients with restrictive disorder in PFT (one of 
them also with decreased TL,CO) had limited gas 
exchange.
Thus, the results of this study showed the 
predominant role of CPET in the evaluation of 
patients with sarcoidosis, since it allowed to iden-
tify changes that were not noticeable in exams at 
rest. It allowed for a better understanding of the 
underlying pathophysiological changes and the 
most correct adjustments of therapies.
As an asset in the integration of clinical, 
imaging and respiratory function results, CPET 
is, however, an exam that is not systematically 
requested in patients with sarcoidosis, justify-
ing the small number of our sample. In subjects 
with cardiovascular limitation without previous 
known cardiac changes, it was possible to raise 
the hypothesis of cardiac involvement by sarcoid-
osis, highlighting the need for a directed study.
Ultimately, it should be noted that in view of 
the clinical, imaging and functional dissociation, 
CPET allowed decisions to be made regarding 
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